CD48: A co-stimulatory receptor of immunity.

Department of Pharmacology and Experimental Therapeutics, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
The international journal of biochemistry & cell biology (Impact Factor: 4.24). 01/2011; 43(1):25-8. DOI: 10.1016/j.biocel.2010.09.001
Source: PubMed

ABSTRACT The CD48 molecule is a glycosyl-phosphatidyl-inositol (GPI)-anchored cell-surface protein of the CD2 family of molecules. Originally described on virally-induced B cells, CD48 has been found on various hematopoietic cells, and its expression is regulated by viral and bacterial products and immune-associated proteins. CD48 binds CD2 and other molecules, yet its high-affinity ligand in both mouse and human systems is 2B4. Despite its lack of an intracellular domain, stimulation of CD48 induces rearrangement of signaling factors in lipid rafts, Lck-kinase activity, and tyrosine phosphorylation. As an adhesion and co-stimulatory molecule, CD48 induces numerous effects in B and T lymphocytes, natural killer cells, mast cells, and eosinophils. Some of these depend upon cell-cell interactions via 2B4-CD48 binding. The structural and phenotypic characteristics of CD48, and its role in physiological and pathophysiological processes, are reviewed herein. Possible CD48-based applications for immune-impaired and inflammatory disorders are discussed as well.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The cell surface molecule 2B4 (CD244) is an important regulator of lymphocyte activation, and its role in anti-viral immunity and lymphoproliferative disorders is well established. Though also expressed on mast cells and eosinophils, the functions of 2B4 on these allergy-orchestrating cells remain unclear. We therefore aimed to investigate the role of 2B4 on murine mast cells and eosinophils, and how this molecule affects allergic and non-allergic inflammatory processes involving these effector cells. Experiments in bone marrow-derived cultures revealed an inhibitory effect for 2B4 in mast cell degranulation, but also an opposing stimulatory effect in eosinophil migration and delayed activation. Murine disease models supported the dual 2B4 function: In 2B4-/- mice with non-allergic peritonitis and mild atopic dermatitis, modest infiltrates of eosinophils into the peritoneum and skin (respectively) confirmed that 2B4 boosts eosinophil trafficking., In a chronic atopic dermatitis model, 2B4-/- mice showed, over-degranulated mast cells, confirming the inhibiting 2B4 effect on mast cell activation. This multifunctional 2B4 profile unfolded in inflammation resembles a similar mixed effect of 2B4 in NK cells. Taken together, our findings provide evidence for physiological 2B4 stimulatory/inhibitory effects in mast cells and eosinophils, pointing to a complex role for 2B4 in allergy.Journal of Investigative Dermatology accepted article preview online, 07 July 2014; doi:10.1038/jid.2014.280.
    Journal of Investigative Dermatology 07/2014; 134(12). DOI:10.1038/jid.2014.280 · 6.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mast cells and basophils (MCs/Bs) play a crucial role in type I allergy, as well as in innate and adaptive immune responses. These cells mediate their actions through soluble mediators, some of which are targeted therapeutically by, for example, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists. Recently, considerable progress has been made in developing new drugs that target additional MC/B mediators or receptors, such as serine proteinases, histamine 4-receptor, 5-lipoxygenase-activating protein, 15-lipoxygenase-1, prostaglandin D2, and proinflammatory cytokines. Mediator production can be abrogated by the use of inhibitors directed against key intracellular enzymes, some of which have been used in clinical trials (eg, inhibitors of spleen tyrosine kinase, phosphatidylinositol 3-kinase, Bruton tyrosine kinase, and the protein tyrosine kinase KIT). Reduced MC/B function can also be achieved by enhancing Src homology 2 domain-containing inositol 5' phosphatase 1 activity or by blocking sphingosine-1-phosphate. Therapeutic interventions in mast cell-associated diseases potentially include drugs that either block ion channels and adhesion molecules or antagonize antiapoptotic effects on B-cell lymphoma 2 family members. MCs/Bs express high-affinity IgE receptors, and blocking their interactions with IgE has been a prime goal in antiallergic therapy. Surface-activating receptors, such as CD48 and thymic stromal lymphopoietin receptors, as well as inhibitory receptors, such as CD300a, FcγRIIb, and endocannabinoid receptors, hold promising therapeutic possibilities based on preclinical studies. The inhibition of activating receptors might help prevent allergic reactions from developing, although most of the candidate drugs are not sufficiently cell specific. In this review recent advances in the development of novel therapeutics toward different molecules of MCs/Bs are presented.
    The Journal of allergy and clinical immunology 04/2014; 134(3). DOI:10.1016/j.jaci.2014.03.007 · 11.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Receptors of the signalling lymphocyte-activation molecules (SLAM) family are involved in the functional regulation of a variety of immune cells upon engagement through homotypic or heterotypic interactions amongst them. Here we show that murine cytomegalovirus (MCMV) dampens the surface expression of several SLAM receptors during the course of the infection of macrophages. By screening a panel of MCMV deletion mutants, we identified m154 as an immunoevasin that effectively reduces the cell-surface expression of the SLAM family member CD48, a high-affinity ligand for natural killer (NK) and cytotoxic T cell receptor CD244. m154 is a mucin-like protein, expressed with early kinetics, which can be found at the cell surface of the infected cell. During infection, m154 leads to proteolytic degradation of CD48. This viral protein interferes with the NK cell cytotoxicity triggered by MCMV-infected macrophages. In addition, we demonstrate that an MCMV mutant virus lacking m154 expression results in an attenuated phenotype in vivo, which can be substantially restored after NK cell depletion in mice. This is the first description of a viral gene capable of downregulating CD48. Our novel findings define m154 as an important player in MCMV innate immune regulation.
    PLoS Pathogens 03/2014; 10(3):e1004000. DOI:10.1371/journal.ppat.1004000 · 8.06 Impact Factor


Available from